Reduction of digoxin effect during the digoxin‐quinidine interaction

G. Das,C. E. Barr,J. Carlson

DOI: https://doi.org/10.1038/clpt.1984.36

1984-03-01

Clinical pharmacology and therapy

Abstract:

What problem does this paper attempt to address?

Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses

Yingying Shi,Jiaxin Huang,Yu Liu,Jing Liu,Xuemeng Guo,Jianhua Li,Liming Gong,Xin Zhou,Guofeng Cheng,Yunqing Qiu,Jian You,Yan Lou

DOI: https://doi.org/10.1126/sciadv.abo1827

IF: 13.6

2022-01-01

Science Advances

Abstract:The coronavirus disease 2019 (COVID-19) pandemic underlines the urgent need for effective mRNA vaccines. However, current understanding of the immunological outcomes of mRNA vaccines formulated under different nanoplatforms is insufficient. Here, severe acute respiratory syndrome coronavirus 2 receptor binding domain mRNA delivered via lipid nanoparticle (LNP), cationic nanoemulsion (CNE), and cationic liposome (Lipo) was constructed. Results demonstrated that the structural and biochemical characteristics of nanoparticles shaped their tissue dissemination, cellular uptake, and intracellular trafficking, which eventually determined the activation of antiviral humoral and cellular immunity. Specifically, LNP was mainly internalized by myocyte and subsequently circumvented lysosome degradation, giving rise to humoral-biased immune responses. Meanwhile, CNE and Lipo induced cellular-preferred immunity, which was respectively attributed to the better lysosomal escape in dendritic cells and the superior biodistribution in secondary lymphoid organs. Overall, this study may guide the design and clinical use of mRNA vaccines against COVID-19.
Lipid nanoparticles for mRNA delivery

Xucheng Hou,Tal Zaks,Robert Langer,Yizhou Dong

DOI: https://doi.org/10.1038/s41578-021-00358-0

IF: 83.5

2021-08-10

Nature Reviews Materials

Abstract:Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent and treat various diseases. To function in vivo, mRNA requires safe, effective and stable delivery systems that protect the nucleic acid from degradation and that allow cellular uptake and mRNA release. Lipid nanoparticles have successfully entered the clinic for the delivery of mRNA; in particular, lipid nanoparticle–mRNA vaccines are now in clinical use against coronavirus disease 2019 (COVID-19), which marks a milestone for mRNA therapeutics. In this Review, we discuss the design of lipid nanoparticles for mRNA delivery and examine physiological barriers and possible administration routes for lipid nanoparticle–mRNA systems. We then consider key points for the clinical translation of lipid nanoparticle–mRNA formulations, including good manufacturing practice, stability, storage and safety, and highlight preclinical and clinical studies of lipid nanoparticle–mRNA therapeutics for infectious diseases, cancer and genetic disorders. Finally, we give an outlook to future possibilities and remaining challenges for this promising technology.

materials science, multidisciplinary,nanoscience & nanotechnology
Teachable moments.

K. Velji

Abstract:
Recent Advances in Lipid Nanoparticles for Delivery of mRNA

Lei Yang,Liming Gong,Ping Wang,Xinghui Zhao,Feng Zhao,Zhijie Zhang,Yunfei Li,Wei Huang

DOI: https://doi.org/10.3390/pharmaceutics14122682

IF: 6.525

2022-12-02

Pharmaceutics

Abstract:Messenger RNA (mRNA), which is composed of ribonucleotides that carry genetic information and direct protein synthesis, is transcribed from a strand of DNA as a template. On this basis, mRNA technology can take advantage of the body's own translation system to express proteins with multiple functions for the treatment of various diseases. Due to the advancement of mRNA synthesis and purification, modification and sequence optimization technologies, and the emerging lipid nanomaterials and other delivery systems, mRNA therapeutic regimens are becoming clinically feasible and exhibit significant reliability in mRNA stability, translation efficiency, and controlled immunogenicity. Lipid nanoparticles (LNPs), currently the leading non-viral delivery vehicles, have made many exciting advances in clinical translation as part of the COVID-19 vaccines and therefore have the potential to accelerate the clinical translation of gene drugs. Additionally, due to their small size, biocompatibility, and biodegradability, LNPs can effectively deliver nucleic acids into cells, which is particularly important for the current mRNA regimens. Therefore, the cutting-edge LNP@mRNA regimens hold great promise for cancer vaccines, infectious disease prevention, protein replacement therapy, gene editing, and rare disease treatment. To shed more lights on LNP@mRNA, this paper mainly discusses the rational of choosing LNPs as the non-viral vectors to deliver mRNA, the general rules for mRNA optimization and LNP preparation, and the various parameters affecting the delivery efficiency of LNP@mRNA, and finally summarizes the current research status as well as the current challenges. The latest research progress of LNPs in the treatment of other diseases such as oncological, cardiovascular, and infectious diseases is also given. Finally, the future applications and perspectives for LNP@mRNA are generally introduced.

pharmacology & pharmacy
Chemistry of Lipid Nanoparticles for RNA Delivery

Yulia Eygeris,Mohit Gupta,Jeonghwan Kim,Gaurav Sahay

DOI: https://doi.org/10.1021/acs.accounts.1c00544

2022-01-04

Abstract:Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a homogeneous lipid core. These vesicles are widely used in small-molecule drug and nucleic acid delivery and recently gained much attention because of their remarkable success as a delivery platform for COVID-19 mRNA vaccines. Nonetheless, the utility of transient protein expression induced by mRNA extends far beyond vaccines against infectious diseases─they also hold promise as cancer vaccines, protein replacement therapies, and gene editing components for rare genetic diseases. However, naked mRNA is inherently unstable and prone to rapid degradation by nucleases and self-hydrolysis. Encapsulation of mRNA within LNPs protects mRNA from extracellular ribonucleases and assists with intracellular mRNA delivery.In this Account, we discuss the core features of LNPs for RNA delivery. We focus our attention on LNPs designed to deliver mRNA; however, we also include examples of siRNA-LNP delivery where appropriate to highlight the commonalities and the dissimilarities due to the nucleic acid structure. First, we introduce the concept of LNPs, the advantages and disadvantages of utilizing nucleic acids as therapeutic agents, and the general reasoning behind the molecular makeup of LNPs. We also briefly highlight the most recent clinical successes of LNP-based nucleic acid therapies. Second, we describe the theory and methods of LNP self-assembly. The common idea behind all of the preparation methods is inducing electrostatic interactions between the nucleic acid and charged lipids and promoting nanoparticle growth via hydrophobic interactions. Third, we break down the LNP composition with special attention to the fundamental properties and purposes of each component. This includes the identified molecular design criteria, commercial sourcing, impact on intracellular trafficking, and contribution to the properties of LNPs. One of the key components of LNPs is ionizable lipids, which initiate electrostatic binding with endosomal membranes and facilitate cytosolic release; however, the roles of other lipid components should not be disregarded, as they are associated with stability, clearance, and distribution of LNPs. Fourth, we review the attributes of LNP constructs as a whole that can heavily influence RNA delivery. These attributes are LNP size, charge, internal structure, lipid packing, lipid membrane hydration, stability, and affinity toward biomacromolecules. We also discuss the specific techniques used to examine these attributes and how they can be adjusted. Finally, we offer our perspective on the future of RNA therapies and some questions that remain in the realm of LNP formulation and optimization.
Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery

Jialiang Wang,Yaopeng Ding,Kellie Chong,Meng Cui,Zeyu Cao,Chenjue Tang,Zhen Tian,Yuping Hu,Yu Zhao,Shaoyi Jiang

DOI: https://doi.org/10.3390/vaccines12101148

2024-10-09

Vaccines

Abstract:Introduction: The advent of lipid nanoparticles (LNPs) as a delivery platform for mRNA therapeutics has revolutionized the biomedical field, particularly in treating infectious diseases, cancer, genetic disorders, and metabolic diseases. Recent Advances in Therapeutic LNPs: LNPs, composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG) lipids, facilitate efficient cellular uptake and cytosolic release of mRNA while mitigating degradation by nucleases. However, as synthetic entities, LNPs face challenges that alter their therapeutic efficacy and safety concerns. Toxicity/Reactogenicity/Immunogenicity: This review provides a comprehensive overview of the latest advancements in LNP research, focusing on preclinical safety assessments encompassing toxicity, reactogenicity, and immunogenicity. Summary and Outlook: Additionally, it outlines potential strategies for addressing these challenges and offers insights into future research directions for enhancing the application of LNPs in mRNA therapeutics.

immunology,medicine, research & experimental
Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery

Xiao Xu,Tian Xia

DOI: https://doi.org/10.1021/acsnanoscienceau.2c00062

2023-03-30

ACS Nanoscience Au

Abstract:The success of mRNA vaccines during the COVID-19 pandemic has greatly accelerated the development of mRNA therapy. mRNA is a negatively charged nucleic acid that serves as a template for protein synthesis in the ribosome. Despite its utility, the instability of mRNA requires suitable carriers for in vivo delivery. Lipid nanoparticles (LNPs) are employed to protect mRNA from degradation and enhance its intracellular delivery. To further optimize the therapeutic efficacy of mRNA, site-specific LNPs have been developed. Through local or systemic administration, these site-specific LNPs can accumulate in specific organs, tissues, or cells, allowing for the intracellular delivery of mRNA to specific cells and enabling the exertion of local or systemic therapeutic effects. This not only improves the efficiency of mRNA therapy but also reduces off-target adverse effects. In this review, we summarize recent site-specific mRNA delivery strategies, including different organ- or tissue-specific LNP after local injection, and organ-specific or cell-specific LNP after intravenous injection. We also provide an outlook on the prospects of mRNA therapy.

English Else
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Yeung Wu,Sinuo Yu,Irene de Lazaro,Irene de Lázaro

DOI: https://doi.org/10.1039/d4nr00019f

IF: 6.7

2024-03-20

Nanoscale

Abstract:The remarkable success of two lipid nanoparticle-mRNA vaccines against coronavirus disease (COVID-19) has placed the therapeutic and prophylactic potential of messenger RNA (mRNA) in the spotlight. It has also drawn attention to the indispensable role of lipid nanoparticles in enabling the effects of this nucleic acid. To date, lipid nanoparticles are the most clinically advanced non-viral platforms for mRNA delivery. This is thanks to their favorable safety profile and efficiency in protecting the nucleic acid from degradation and allowing its cellular uptake and cytoplasmic release upon endosomal escape. Moreover, the development of lipid nanoparticle-mRNA therapeutics was already a very active area of research even before the COVID-19 pandemic, which has likely only begun to bear its fruits. In this Review, we first discuss key aspects of the development of lipid nanoparticles as mRNA carriers. We then highlight promising preclinical and clinical studies involving lipid nanoparticle-mRNA formulations against infectious diseases and cancer, and to enable protein replacement or supplementation and genome editing. Finally, we elaborate on the challenges in advancing lipid nanoparticle-mRNA technology to widespread therapeutic use.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry
Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing

Min Qiu,Yamin Li,Hanan Bloomer,Qiaobing Xu

DOI: https://doi.org/10.1021/acs.accounts.1c00500

IF: 24.466

2021-10-20

Accounts of Chemical Research

Abstract:Since the U.S. Food and Drug Administration (FDA) granted emergency use authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has attracted broad attention from the scientific community to investors. When delivered intracellularly, mRNA has the ability to produce various therapeutic proteins, enabling the treatment of a variety of illnesses, including but not limited to infectious diseases, cancers, and genetic diseases. Accordingly, mRNA holds significant therapeutic potential and provides a promising means to target historically hard-to-treat diseases. Current clinical efforts harnessing mRNA-based technology are focused on vaccination, cancer immunotherapy, protein replacement therapy, and genome editing. The clinical translation of mRNA-based technology has been made possible by leveraging nanoparticle delivery methods. However, the application of mRNA for therapeutic purposes is still challenged by the need for specific, efficient, and safe delivery systems.This Account highlights key advances in designing and developing combinatorial synthetic lipid nanoparticles (LNPs) with distinct chemical structures and properties for in vitro and in vivo intracellular mRNA delivery. LNPs represent the most advanced nonviral nanoparticle delivery systems that have been extensively investigated for nucleic acid delivery. The aforementioned COVID-19 mRNA vaccines and one LNP-based small interfering RNA (siRNA) drug (ONPATTRO) have received clinical approval from the FDA, highlighting the success of synthetic ionizable lipids for in vivo nucleic acid delivery. In this Account, we first summarize the research efforts from our group on the development of bioreducible and biodegradable LNPs by leveraging the combinatorial chemistry strategy, such as the Michael addition reaction, which allows us to easily generate a large set of lipidoids with diverse chemical structures. Next, we discuss the utilization of a library screening strategy to identify optimal LNPs for targeted mRNA delivery and showcase the applications of the optimized LNPs in cell engineering and genome editing. Finally, we outline key challenges to the clinical translation of mRNA-based therapies and propose an outlook for future directions of the chemical design and optimization of LNPs to improve the safety and specificity of mRNA drugs. We hope this Account provides insight into the rational design of LNPs for facilitating the development of mRNA therapeutics, a transformative technology that promises to revolutionize future medicine.

chemistry, multidisciplinary
Current landscape of mRNA technologies and delivery systems for new modality therapeutics

Ruei-Min Lu,Hsiang-En Hsu,Ser John Lynon P. Perez,Monika Kumari,Guan-Hong Chen,Ming-Hsiang Hong,Yin-Shiou Lin,Ching-Hang Liu,Shih-Han Ko,Christian Angelo P. Concio,Yi-Jen Su,Yi-Han Chang,Wen-Shan Li,Han-Chung Wu

DOI: https://doi.org/10.1186/s12929-024-01080-z

2024-09-12

Journal of Biomedical Science

Abstract:Realizing the immense clinical potential of mRNA-based drugs will require continued development of methods to safely deliver the bioactive agents with high efficiency and without triggering side effects. In this regard, lipid nanoparticles have been successfully utilized to improve mRNA delivery and protect the cargo from extracellular degradation. Encapsulation in lipid nanoparticles was an essential factor in the successful clinical application of mRNA vaccines, which conclusively demonstrated the technology's potential to yield approved medicines. In this review, we begin by describing current advances in mRNA modifications, design of novel lipids and development of lipid nanoparticle components for mRNA-based drugs. Then, we summarize key points pertaining to preclinical and clinical development of mRNA therapeutics. Finally, we cover topics related to targeted delivery systems, including endosomal escape and targeting of immune cells, tumors and organs for use with mRNA vaccines and new treatment modalities for human diseases.

cell biology,medicine, research & experimental
Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development

Shalmali Shirish Cholkar,Ashwini Ramkrishana Gawade,Ashwin Bhanudas Kuchekar

DOI: https://doi.org/10.13005/bbra/2979

2022-03-31

Biosciences Biotechnology Research Asia

Abstract:The current applications of nanomedicine span from the treatment of an infection right up to the treatment of cancer. Lipid nanoparticles (LNPs) have established themselves as reliable delivery systems for delivering therapeutic agents including nucleic acids since they prevent in vivo degradation of nucleic acids and facilitate their target-specific delivery. The mRNA is one such nucleic acid that is delivered by the LNPs for the treatment of infectious diseases. This review provides a detailed insight into the concept of messenger RNA (mRNA) vaccines, their mechanism of action, manufacturing process, critical considerations in the formulation, development, and manufacturing of these vaccines, and explains the vital role of LNPs in the development of these vaccines. Certain shortcomings of the lipid nanoparticle-mRNA vaccine concerning the in vitro stability of the mRNA and the LNP have also been highlighted in this review.
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.

M. Schäfer,D. Rujescu,I. Giegling,A. Guntermann,A. Erfurth,B. Bondy,H. Möller

DOI: https://doi.org/10.1176/APPI.AJP.158.5.802

IF: 17.7

2001-05-01

American Journal of Psychiatry

Abstract:OBJECTIVE Pharmacogenetic influences on therapeutic response to neuroleptic treatment are poorly understood. This study investigates the association of response to short-term haloperidol treatment with a Taq I polymorphism in the DRD2 gene. METHOD Fifty-seven patients with acute psychosis were treated with haloperidol for up to 28 days. Improvement and response were measured by using the Positive and Negative Syndrome SCALE: Forty-one patients were homozygous for allele 2, and 16 were heterozygous. RESULTS Heterozygous patients showed a greater improvement in positive, but not in negative, symptoms on all treatment days than patients homozygous for allele 2. Differences in improvement of positive symptoms reached statistical significance on days 14, 21, and 28. On treatment day 14, 10 (62.5%) of 16 heterozygous patients had at least 50% improvement of positive symptoms, compared with 11 (28.9%) of 38 homozygous patients. CONCLUSIONS These results support the hypothesis that genetic variations in the DRD2 gene may influence the individual response to antipsychotics.
Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement

Rumiana Tenchov,Robert Bird,Allison E Curtze,Qiongqiong Zhou

DOI: https://doi.org/10.1021/acsnano.1c04996

IF: 17.1

2021-11-23

ACS Nano

Abstract:Lipid nanoparticles (LNPs) have emerged across the pharmaceutical industry as promising vehicles to deliver a variety of therapeutics. Currently in the spotlight as vital components of the COVID-19 mRNA vaccines, LNPs play a key role in effectively protecting and transporting mRNA to cells. Liposomes, an early version of LNPs, are a versatile nanomedicine delivery platform. A number of liposomal drugs have been approved and applied to medical practice. Subsequent generations of lipid nanocarriers, such as solid lipid nanoparticles, nanostructured lipid carriers, and cationic lipid-nucleic acid complexes, exhibit more complex architectures and enhanced physical stabilities. With their ability to encapsulate and deliver therapeutics to specific locations within the body and to release their contents at a desired time, LNPs provide a valuable platform for treatment of a variety of diseases. Here, we present a landscape of LNP-related scientific publications, including patents and journal articles, based on analysis of the CAS Content Collection, the largest human-curated collection of published scientific knowledge. Rising trends are identified, such as nanostructured lipid carriers and solid lipid nanoparticles becoming the preferred platforms for numerous formulations. Recent advancements in LNP formulations as drug delivery platforms, such as antitumor and nucleic acid therapeutics and vaccine delivery systems, are discussed. Challenges and growth opportunities are also evaluated in other areas, such as medical imaging, cosmetics, nutrition, and agrochemicals. This report is intended to serve as a useful resource for those interested in LNP nanotechnologies, their applications, and the global research effort for their development.
Advances in the study of LNPs for mRNA delivery and clinical applications

Bili Wang,Biao Shen,Wenqing Xiang,Hongqiang Shen

DOI: https://doi.org/10.1007/s11262-024-02102-6

2024-08-22

Virus Genes

Abstract:Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, were major achievements in the history of vaccine development. Lipid nanoparticles (LNPs), one of the most superior non-viral delivery vectors available, have made many exciting advances in clinical translation as part of the COVID-19 vaccine and therefore has the potential to accelerate the clinical translation of many gene drugs. In addition, due to these small size, biocompatibility and excellent biodegradability, LNPs can efficiently deliver nucleic acids into cells, which is particularly important for current mRNA therapeutic regimens. LNPs are composed cationic or pH-dependent ionizable lipid bilayer, polyethylene glycol (PEG), phospholipids, and cholesterol, represents an advanced system for the delivery of mRNA vaccines. Furthermore, optimization of these four components constituting the LNPs have demonstrated enhanced vaccine efficacy and diminished adverse effects. The incorporation of biodegradable lipids enhance the biocompatibility of LNPs, thereby improving its potential as an efficacious therapeutic approach for a wide range of challenging and intricate diseases, encompassing infectious diseases, liver disorders, cancer, cardiovascular diseases, cerebrovascular conditions, among others. Consequently, this review aims to furnish the scientific community with the most up-to-date information regarding mRNA vaccines and LNP delivery systems.
Delivery Strategies for mRNA Vaccines

Sivakumar Ramachandran,Soumya Ranjan Satapathy,Tathagata Dutta

DOI: https://doi.org/10.1007/s40290-021-00417-5

Abstract:The therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) approval of patisiran (Onpattro™) for hereditary ATTR amyloidosis. This was largely made possible by major advances in the formulation technology for stabilized lipid-based nanoparticles (LNPs). Design of the cationic ionizable lipids, which are a key component of the LNP formulations, with an acid dissociation constant (pKa) close to the early endosomal pH, would not only ensure effective encapsulation of mRNA into the stabilized lipoplexes within the LNPs, but also its subsequent endosomal release into the cytoplasm after endocytosis. Unlike other gene therapy modalities, which require nuclear delivery, the site of action for exogenous mRNA vaccines is the cytosol where they get translated into antigenic proteins and thereby elicit an immune response. LNPs also protect the mRNA against enzymatic degradation by the omnipresent ribonucleases (RNases). Cationic nano emulsion (CNE) is also explored as an alternative and relatively thermostable mRNA vaccine delivery vehicle. In this review, we have summarized the various delivery strategies explored for mRNA vaccines, including naked mRNA injection; ex vivo loading of dendritic cells; CNE; cationic peptides; cationic polymers and finally the clinically successful COVID-19 LNP vaccines (Pfizer/BioNTech and Moderna vaccines)-their components, design principles, formulation parameter optimization and stabilization challenges. Despite the clinical success of LNP-mRNA vaccine formulations, there is a specific need to enhance their storage stability above 0 °C for these lifesaving vaccines to reach the developing world.
Lipid carriers for mRNA delivery

Wanting Zhang,Yuxin Jiang,Yonglong He,Hamza Boucetta,Jun Wu,Zhongjian Chen,Wei He

DOI: https://doi.org/10.1016/j.apsb.2022.11.026

IF: 14.903

2022-12-02

Acta Pharmaceutica Sinica B

Abstract:Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, including viral infection and cancer. Especially, mRNA-based vaccines, as a new type of vaccine, have played a leading role in fighting against the current global pandemic of COVID-19. However, the inherent drawbacks, including large size, negative charge, and instability, hinder its use as a therapeutic agent. Lipid carriers are distinguishable and promising vehicles for mRNA delivery, owning the capacity to encapsulate and deliver negatively charged drugs to the targeted tissues and release cargoes at the desired time. Here, we first summarized the structure and properties of different lipid carriers, such as liposomes, liposome-like nanoparticles, solid lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanoemulsions, exosomes and lipoprotein particles, and their applications in delivering mRNA. Then, the development of lipid-based formulations as vaccine delivery systems was discussed and highlighted. Recent advancements in the mRNA vaccine of COVID-19 were emphasized. Finally, we described our future vision and perspectives in this field.

pharmacology & pharmacy
Isolation of influenza A virus in Reye's syndrome.

P. Visudhiphan,K. Chatiyanonda

1975-06-01

Southeast asian journal of tropical medicine and public health

Abstract:Reye's syndrome, or encephalopathy with fatty degeneration of the viscera, is an acute and often fatal childhood illness in which signs of brain swelling and liver enlargement develop rapidly (Olson et at., 1970). The course of the disease is characteristic, and, once unconsciousness has developed, it can be diagnosed without difficulty. This is a common disorder in north-eastern Thailand and probably affects hundreds of children· annually (Olson et at., 1970; 1971). Sporadic cases are also found in the other parts of the country (Visudhiphan, unpublished data).
Challenges and advances of the stability of mRNA delivery therapeutics

Jin Zhai,Trystin Cote,Yupeng Chen

DOI: https://doi.org/10.18609/nai.2024.015

Abstract:mRNA therapeutics have garnered significant attention in the biomedical realm, showing immense potential across a spectrum of applications from COVID-19 to cancer treatments. Their ability to trigger precise protein expression, particularly in genome editing, is pivotal in minimizing off-target effects. At the core of mRNA therapy lies a dual-component system, comprising the mRNA itself and a delivery vehicle. The breakthrough success of novel COVID-19 vaccines has catapulted lipid nanoparticles to prominence as the preferred delivery vehicle. However, despite their US FDA approval and efficacy, lipid nanoparticles face a significant challenge: poor stability at room temperature, which limits their applications in various geographic regions with disparities in infrastructure and technology. This review aims to dissect the issue of stability inherent in lipid nanoparticles and other mRNA delivery platforms such as polymer-based materials and protein derivative materials. We herein endeavor to unravel the factors contributing to their instability and explore potential strategies to enhance their stability. By doing so, we provide a comprehensive analysis of the current landscape of mRNA delivery systems, highlighting both their successes and limitations, and paving the way for future advancements in this rapidly evolving field.
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging

Han Na Jung,Seok-Yong Lee,Somin Lee,Hyewon Youn,Hyung-Jun Im

DOI: https://doi.org/10.7150/thno.77259

IF: 11.6

2022-10-24

Theranostics

Abstract:Lipid nanoparticles (LNPs) have been one of the most successful nano-delivery vehicles that enable efficient delivery of cytotoxic chemotherapy agents, antibiotics, and nucleic acid therapeutics. During the coronavirus disease (COVID-19) pandemic, LNP-based COVID-19 messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna have been successfully developed, resulting in global sales of $37 billion and $17.7 billion, respectively, in 2021. Based on this success, the development of multiple LNP-based RNA therapeutics is gaining momentum due to its potential in vaccines and therapeutics for various genetic diseases and cancers. Furthermore, imaging techniques can be utilized to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) effects, which helps target discovery and accelerates the development of LNP-based mRNA therapies. A thorough introduction and explanation of the components of LNPs and its functions along with various production methods of formulating LNPs are provided in this review. Furthermore, recent advances in LNP-based RNA therapeutics in clinics and clinical trials are explored. Additionally, the evaluation of PK/PD of LNPs for RNA delivery and the current and potential roles in developing LNP-based mRNA pharmaceutics through imaging techniques will be discussed.
Strategies for Organ-Targeted mRNA Delivery by Lipid Nanoparticles.

Hui Fan,Hangping Liao,Jing Liao,Jinjin Chen,Ling Zeng,Xinxiu Cao

DOI: https://doi.org/10.1002/wnan.2004

2024-09-01

Abstract:Messenger RNA (mRNA) technology has rapidly evolved, significantly impacting various therapeutic applications, including vaccines, protein replacement, and gene editing. Lipid nanoparticles (LNPs) have emerged as a pivotal nonviral vector for mRNA delivery, crucial for organ-targeted therapies. Despite their success, most LNP formulations predominantly target the liver, limiting their use in nonliver diseases. This review explores strategies to achieve organ-specific mRNA delivery using LNPs, including the discovery of new lipid structures, modification of targeting ligands, incorporation of additional components, and optimization of LNP formulations. These advancements aim to enhance the precision and efficacy of mRNA therapeutics across a broader range of diseases.

Medicine

Reduction of digoxin effect during the digoxin‐quinidine interaction

Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses

Lipid nanoparticles for mRNA delivery

Teachable moments.

Recent Advances in Lipid Nanoparticles for Delivery of mRNA

Chemistry of Lipid Nanoparticles for RNA Delivery

Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery

Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery

Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing

Current landscape of mRNA technologies and delivery systems for new modality therapeutics

Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.

Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement

Advances in the study of LNPs for mRNA delivery and clinical applications

Delivery Strategies for mRNA Vaccines

Lipid carriers for mRNA delivery

Isolation of influenza A virus in Reye's syndrome.

Challenges and advances of the stability of mRNA delivery therapeutics

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging

Strategies for Organ-Targeted mRNA Delivery by Lipid Nanoparticles.